Clarification Letter dated April 27, 2022 between the Registrant and EirGenix, Inc
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED.
Exhibit 10.1
April 27, 2022
Albert C. Lin
Business Development Director
EirGenix, Inc.
No. 101, Lane 169
Kangning Street, Xizhi District
New Taipei City 22180, Taiwan
RE: Clarification regarding certain pricing terms in the Amended and Restated Supply Agreement between Bolt Biotherapeutics, Inc. and EirGenix, Inc. dated January 25, 2022
Dear Albert,
The purpose of this letter is to document the parties' agreement regarding pricing of Antibody at the [***] under Section5.1 of the above referenced agreement. Capitalized terms used herein and not otherwise defined in this letter shall have the meaning assigned to such term in the agreement.
The parties agree that if Bolt orders a batch of Antibody [***], then the Supply Price for such Antibody would be [***] per gram. This price would apply in the case where the batches [***].
Please acknowledge EirGenix's agreement with the foregoing by signing below and returning a countersigned version of this letter to me.
Sincerely,
Grant Yonehiro
Chief Business Officer
Bolt Biotherapeutics, Inc.
The undersigned acknowledges and agrees with and to the terms of this letter.
On behalf of EirGenix, Inc.
By: /s/ Lee-Cheng Liu
Names: Lee-Cheng Liu
Title: President & CEO
Date: 2022/05/06
|www.boltbio.com | 900 Chesapeake Drive | Redwood City | CA | 94063 | | 1
